SMYD3 and cancer: Because SMYD3 overexpression is frequent in cancer and its genetic depletion has no developmental consequences identified to date (ref. 19; International Knockout Mouse Consortium), an interesting possibility to optimize alkylation-based therapies would be to combine them with SMYD3 pharmacologic inhibition.